Top of page
Health

Cycles of Reward: New Insight into ADHD Treatment

girl with ADHD playing

Attention-Deficit Hyperactivity Disorder (ADHD) is a widespread condition with complex underlying causes. A stimulant drug called methylphenidate is a common ADHD treatment that impacts the brain’s levels of dopamine, a neurotransmitter involved in systems of reward; however, methylphenidate has a potential for abuse, and its therapeutic effects are poorly understood.

To explore methylphenidate’s varied interactions with dopamine systems in the brain, researchers at the Okinawa Institute of Science and Technology Graduate University (OIST) in collaboration with scientists at the University of Otago and the University of Auckland in New Zealand, investigated the actions of the drug in rats. Using dopamine cell recordings, electrochemical monitoring and computer modeling, they discovered a type of feedback loop that modulates dopamine levels in the rats’ brains in response to the drug. This regulatory process may shed light on methylphenidate’s therapeutic properties in ADHD. The researchers’ findings are published in Progress in Neurobiology.

“We know quite a bit about how methylphenidate works at the molecular level, but not how it affects greater neural systems. It’s still a mystery how this drug improves symptoms of ADHD,” said Professor Jeff Wickens of OIST’s Neurobiology Research Unit. “This mystery leads us to explore how different parts of the brain interact to produce therapeutic effects.”

To carry out their research, the international team administered methylphenidate at a concentration of 5.0 mg/kg to a group of adult male rats, while a control group received no drugs. After surgically implanting electrodes in the rats’ brains, the researchers used an electrochemical technique called voltammetry to monitor real-time changes in cellular dopamine concentration in brain regions involved in ADHD. The researchers also took measurements in live brain slices of rats’ midbrains and forebrains.

To help understand the data, the scientists at OIST, including technician Kavinda Liyanagama, designed a computer program to model the effects of methylphenidate on dopamine systems.

You might also like

kid boy Upset, sitting in the dark kid boy Upset, sitting in the dark

Childhood maltreatment accounts to 40% of mental health conditions

The mental health conditions examined were anxiety, depression, harmful alcohol…

Doctor holding a digital tablet with x-ray of brain and skull skeleton Doctor holding a digital tablet with x-ray of brain and skull skeleton

WHO and France host high-level meeting to tackle meningitis

Global leaders highlight the need to defeat meningitis – a leading…

a teenage with autism relaxing with rocking chair a teenage with autism relaxing with rocking chair

Specialist autism diagnostic service launches for at-risk young people

A first-of-its-kind service is underway from this month to provide…

Shelby Rowe, second from right, executive director of the Suicide Prevention Resource Center at the University of Oklahoma, speaks at a White House panel discussion Tuesday with actress Ashley Judd, second from left, and singer-songwriter Aloe Blacc, right. The discussion, facilitated by U.S. Surgeon General Vivek Murthy, M.D., MBA, left, was held to mark the release of the National Strategy for Suicide Prevention. Shelby Rowe, second from right, executive director of the Suicide Prevention Resource Center at the University of Oklahoma, speaks at a White House panel discussion Tuesday with actress Ashley Judd, second from left, and singer-songwriter Aloe Blacc, right. The discussion, facilitated by U.S. Surgeon General Vivek Murthy, M.D., MBA, left, was held to mark the release of the National Strategy for Suicide Prevention.

University of Oklahoma assists in New National Suicide Prevention Plan

The Biden-Harris Administration, through the U.S. Department of Health and…